You are here

Valens: A Mass Spectrometry-Based Antibody Sequencing Tool by Digital Proteomics

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM103346-01
Agency Tracking Number: R43GM103346
Amount: $480,109.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PA11-215
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4519 49th Street
SAN DIEGO, CA 92115-3238
United States
DUNS: 31092123
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (703) 727-0820
Business Contact
Phone: (703) 727-0820
Research Institution

DESCRIPTION (provided by applicant): Monoclonal antibodies exhibit high specificity for target molecules and for that reason have been successfully utilized as therapeutic and diagnostic agents. The sequence of amino acids comprising the primary structureof an antibody is largely responsible for its binding preference and efficacy. Therefore, antibody sequencing is a central requirement for the development of novel antibody therapies. We propose a method of performing antibody sequencing directly from theprotein sequence, without requiring the source cell, which makes it practical for many lab and clinical settings. In addition, our proposed computational method is fully automated, and will increase throughput by dramatically reducing the time required forsequencing from weeks to hours. We plan to implement our method in both a stand-alone tool that may be run on a single desktop computer, or make use of the vast resources available in cloud computing. We will also provide an in-house sequencing servicefor users without access to the mass spectrometry equipment or computing resources. PUBLIC HEALTH RELEVANCE: Characterizing the sequence of an antibody is a prerequisite for the development of antibody based therapies and diagnostic methods, which represent a growing segment of the drug market. We propose a novel computational method of antibody sequencing based on mass spectrometry, which will dramatically increase the rate of antibody characterization, and reduce the time from development in thelab to treatment in the clinic.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government